Why the study?
Does ticagrelor reduce the composite of cardiac death, myocardial infarction and stroke compared with clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention?
Does ticagrelor reduce the composite of cardiac death, myocardial infarction and stroke compared with clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention?
An editorial discussing recent evidence that questions the guideline-recommended role of ticagrelor as a first-line antiplatelet option in ACS patients undergoing PCI.
In patients with an acute coronary syndrome (ACS), one year of dual antiplatelet therapy (DAPT) with low-dose aspirin and a platelet P2Y12 receptor inhibitor is the recommended strategy for pharmacological prevention of recurring atherothrombotic events1. Based on guidelines, prasugrel and ticagrelor are the preferred options for combination therapy with aspirin, owing to the results of two international trials unequivocally demonstrating a reduction in the composite of cardiac death, myocardial infarction and stroke compared with clopidogrel2,3. Now, a study from Zocca and colleagues questions the role of ticagrelor as a first-line antiplatelet option in patients with ACS undergoing percutaneous ...
No takes yet. Share an insight, caveat, or question.
Davide Capodanno (2017) conducted an editorial in Acute coronary syndrome (ACS). Prasugrel and ticagrelor (Dual antiplatelet therapy) vs. Clopidogrel was evaluated on Composite of cardiac death, myocardial infarction and stroke.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: